Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
    • What are Neuroendocrine Cancers?
    • What are Pheos & Paras?
    • NET Symptoms
    • NET Types
    • Causes
    • Treatments
    • Grades
    • Diagnosis
    • Prognosis
    Consider the Grey Area
  • Patients & Carers
    • Patient & Carer Support
    • Patient Resources
    • Optimal Care Pathway
    • NET Nurse
    • Patient Stories
    • Share your Story
    • Australian NET Specialists
    • Clinical Trials
    • Living with NETS
    • Specialist Support Services
    Consider the Grey Area
  • Healthcare Professionals
    • Optimal Care Pathway
    • Professional Learning
    • Patient Referral
    • Clinical Trials
    • NET Symptoms
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order Booklets & Resources
    Consider the Grey Area
  • Get Involved
    • Advocate for Us
    • Share your Story
    • Donate
    • Fundraise
    • Events
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Volunteer
    Senate MailChimp
  • March4NETs
NET Nurse
Donate

Home » Advocacy » ENETS session – High grade classification

ENETS session – High grade classification

  • March 26, 2019

(by Meredith Cummins, NSW Project Officer)

The 16th ENETs Conference for the Diagnosis and Treatment of Neuroendocrine Tumour Disease was a wonderful opportunity to network internationally and gain knowledge and insight into the great work being done in this field. There were so many fabulous sessions, so many that it was difficult to report on them all. The session below was part of the ENETs / European Society of Pathology (ESP) New Classification / Making Sense of High-grade Neoplasms. Within this session Dr Jean – Yves Scoazec from France presented Pulmonary and Digestive High Grade NENs – Where are they similar? The following highlights the grading and a conclusion of the grading. So much work is being done to better define the respective NETs so that treatment can be customized for better management.

WHO classification of digestive NENs (2019) is divided into-

  • Neuroendocrine tumour G1 – differentiation  – well differentiated, mitotic index ,2 mitoses / 2mm2, Ki 67 Index <= 2% (Low Grade)
  • Neuroendocrine tumour G2 – differentiation – well differentiated ,mitotic index 2-20 mitoses / 2mm2, Ki 67 Index – 3-20 % (Intermediate Grade)
  • Neuroendocrine G3 – differentiation – well differentiated, mitotic index  20 mitoses / 2 mm2, Ki 67 index >20% (High Grade)
  •  Large Cell neuroendocrine carcinoma – differentiation – poorly differentiated, mitotic index 20 mitoses / 2mm2, Ki 67 index >20% (High to very High Grade)
  • Small cell neuroendocrine carcinoma – differentiation  – poorly differentiated, mitotic index 20 mitoses / 2mm2, Ki 67 index  > 20% (High to very High Grade)

Next WHO classification of Lung NENs (20..)

  • Typical Carcinoid – differentiation  – well differentiated, necrosis  – absent, Mitotic index , 2 mitoses / 10HPF (2mm2)( Low Grade)
  • Atypical carcinoid – well differentiated, necrosis – possible, focal, mitotic index – 2-10 mitoses / 10HPF (2mm2) (Intermediate Grade)
  • Supracarcinoid – differentiation – well differentiated – (High Grade)
  • Large Cell neuroendocrine carcinoma – differentiation – poorly differentiated, necrosis – frequent, extensive, mitotic index  >10mitoses/ 10HPF (2mm2) – (High to very High Grade)
  • Small Cell neuroendocrine carcinoma – differentiation  – poorly differentiated, necrosis  – frequent, extensive, mitotic index > 10 mitoses / 10HPF (2mm2) – (High to very High Grade)

So in conclusion :

  • Lung and digestive high grade NENs share some similarities but they also express site specific feature
  • High grade NETs exist in both the digestive system and the lung: they require an accurate diagnosis and probably, an adapted treatment
  • Small Cell neuroendocrine carcinoma is a distinctive entity
  • Large Cell neuroendocrine carcinoma is a diverse category with a need for a reevaluation of our diagnostic and therapeutic approaches

Share this post

Recent posts

NECA CEO Meredith Cummins is Now INCA President

February 16, 2026

Raising awareness of neuroendocrine cancer at Peninsula Bays Hospital Wellness Day

February 9, 2026

Raising Awareness for NETs on World Cancer Day in WA

February 4, 2026

Australia delivers excellent cancer care, but not equally

February 4, 2026
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousENETs Overview
NextVCCC Monday Lunch Live eventsNext

Related Posts

Raising awareness of neuroendocrine cancer at Peninsula Bays Hospital Wellness Day

Thank you to NET patient Kristen Leknius for hosting a neuroendocrine cancer information table at the February Peninsula Bays Hospital Wellness Day. With around 250

Raising Awareness for NETs on World Cancer Day in WA

On World Cancer Day, our WA NET Nurse, Tammy, proudly represented NeuroEndocrine Cancer Australia (NECA) at an awareness event held at Sir Charles Gardiner Hospital.

Australia delivers excellent cancer care, but not equally

Meredith Cummins is CEO of NeuroEndocrine Cancer Australia and incoming President of the International Neuroendocrine Cancer Alliance, representing patient advocacy groups worldwide. Every World Cancer

AUS-NET Update, January 2026

The AUS-NET trial commenced in 2022 and is running through to 2027. Across the five Centres of Excellence—The Queen Elizabeth Hospital, Royal North Shore Hospital,

View All

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Patients & Carers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

Healthcare Professionals

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2026 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin